Sartorius Stedim Biotech (SSB), has developed a fully integrated technology platform to meet the requirements of upstream bioprocessing.
The upstream technology platform, which combines a range of products and services developed by SSB, addresses the challenge of cutting early-stage drug development timelines without compromising on product quality, process productivity or robustness. It claims biopharmaceutical manufacturers will be able to reach the clinic in 14 months by leveraging this new platform.
The royalty-free CHO expression platform of SSB’s subsidiary Cellca delivers the titers required to meet companies’ cost of goods objectives. Cellca can establish a research cell bank for clients within four months. The automated ambr15 micro bioreactor system is capable of controlling 24 or 48 micro bioreactor experiments. The system accelerates clone selection and scales up readily to BIOSTAT STR single-use bioreactors, which biomanufacturers have successfully implemented at pilot and GMP production scales. To reduce early stage development timelines even further,
Sartorius Stedim Biotech has integrated more than one hundred off-the-shelf and pre-qualified assays from BioOutsource into its platform, allowing the rapid testing and analysis of biosimilar products.
Stefan Schlack, Senior Vice President Marketing and Product Management Bioprocess Solutions at Sartorius Stedim Biotech said: “Our upstream platform is currently unique on the market and addresses customers’ needs and challenges of the biopharma industry in an exceptional way. It connects outstanding process technologies and brings biology to single-use bioprocessing. We are therefore introducing a whole new level of efficiency in upstream processing.”
